Guardant Health stock hits 52-week high at 120.74 USD By Investing.com
Guardant Health Inc. (GH) stock reached a new 52-week high of $120.74, marking a significant 210% increase over the past year. Despite this surge, InvestingPro data suggests the stock is in overbought territory and appears overvalued relative to its Fair Value, although it boasts a market cap of $15.98 billion and 40% revenue growth. The company recently received FDA approval for its G360 Liquid CDx test and reported Q1 2026 revenue of $302 million, surpassing forecasts, while analysts like TD Cowen maintained a Buy rating with a $127.00 price target.
Guardant Health stock gains on early FDA approval for G360 test
Guardant Health (NASDAQ: GH) stock gained significantly after the FDA granted early approval for its G360 Liquid CDx test. TD Cowen reiterated a Buy rating and a $127.00 price target, estimating the approval could boost 2027 and 2028 sales by 9% and 12% respectively, assuming ADLT pricing. The stock closed up 17%, reaching $114.18, and analysts maintain a "Strong Buy" consensus.
Why Guardant Health (GH) Is Up 16.8% After Hiking 2026 Revenue Guidance on Shield Momentum
Guardant Health's stock rose 16.8% after the company raised its 2026 revenue guidance to US$1.30–US$1.32 billion, driven by strong adoption of its Shield colorectal cancer screening test. While the increased guidance highlights confidence in Shield's momentum and broader market access through Quest Diagnostics, the company continues to face widening losses and cash burn. The investment narrative remains centered on Shield's potential to scale into a commercially reimbursed market, balanced against ongoing funding and dilution risks.
[144] Guardant Health, Inc. SEC Filing
This article details Guardant Health, Inc.'s SEC Form 144 filing, a notice of proposed sale of securities under Rule 144. The filing indicates a sale of 30,000 shares of common stock with an aggregate market value of $3,195,345.00, acquired on October 1, 2023, through equity compensation. It also notes recent news and SEC filings for Guardant Health, emphasizing ongoing financial and regulatory activities.
Guardant Health (NASDAQ: GH) affiliate sale notice; 1,300 shares sold previously
Guardant Health (NASDAQ: GH) has filed a Form 144 proposing affiliate sales, including restricted stock lapses of 33 shares on September 17, 2025, and 217 shares on October 17, 2025. The filing also notes a stock option exercise for 1,000 shares on May 20, 2026, described as a broker payment for a cashless exercise. Previously, Manuel Hidalgo Medina sold 1,300 shares on March 6, 2026, for $118,997.
Guardant Health Stock Rallies After Shield-Fueled Earnings Beat
Guardant Health (GH) stock rallied 13.38% after strong Q1 earnings, fueled by a 48% year-over-year revenue increase to $302 million and a significant surge in Shield screening revenue. The company raised its FY26 revenue outlook to $1.30B–$1.32B and secured a nationwide collaboration with Quest Diagnostics, which analysts expect to drive further growth. Despite continued negative free cash flow, bullish ratings from major banks and increased price targets reflect confidence in Guardant Health's growth trajectory and market leadership in liquid biopsy.
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test - Guardant Health (NASDAQ:GH)
Guardant Health received FDA approval for its Guardant360 Liquid CDx test, an expanded liquid biopsy panel for advanced cancer patients. This updated test, powered by the proprietary Smart Platform, combines genomic and epigenomic insights from a single blood sample, offering faster turnaround times and broader clinical utility. The approval also transfers seven previous companion diagnostic indications to the new test, which features a 100 times wider genomic footprint than its predecessor.
Guardant Health (GH) Shares Rise Following FDA Approval of Guardant360 Liquid CDx
Guardant Health (GH) shares rose following FDA approval of its Guardant360 Liquid CDx, an enhanced blood-based cancer test. This new test offers improved sensitivity over its predecessor, aiming to refine treatment decisions for advanced cancer patients. Despite strong growth potential and a high price-to-sales ratio, the company faces challenges with low financial strength, profitability, and significant insider selling.
Guardant Health Says US FDA Approved Liquid Biopsy Test
Guardant Health announced that its liquid biopsy test has received approval from the US FDA. This news led to a significant increase in Guardant Health's stock, up 13.60%. The article also briefly mentions Unity Software's Q4 earnings, reporting increased revenue but a quarterly loss.
Guardant Health receives FDA approval for expanded liquid biopsy test
Guardant Health Inc. has received FDA approval for its expanded liquid biopsy test, Guardant360 Liquid CDx, which offers both genomic and epigenomic analysis for various cancers. The company's stock has surged by 146% over the past year, reflecting investor confidence. This new test significantly broadens the genomic footprint assessed compared to its predecessor and provides rapid results, with coverage from Medicare and commercial insurers.
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health announced that the FDA has approved its new Guardant360 Liquid CDx, a liquid biopsy panel that integrates genomic and epigenomic insights for advanced cancer treatment selection. This new test is the largest FDA-approved liquid biopsy panel, offering a 100x wider genomic footprint than its predecessor and delivering results in as little as seven days. The approval strengthens Guardant's leadership in precision oncology by providing a more comprehensive and actionable view of cancer from a simple blood draw.
Guardant Health (GH) director sells 116 shares after exercising 250 RSUs
Guardant Health director Tariq Musa sold 116 common shares at $95.96 each after exercising 250 restricted stock units (RSUs) on May 15, 2026. Following these transactions, Musa directly holds 8,662 Guardant Health common shares and 2,499 RSUs remain outstanding. The RSUs granted on March 6, 2023, vest over a four-year period, with 25% having vested in March 2024 and the remainder vesting monthly over three years.
Director at Guardant Health (NASDAQ: GH) gains 232 shares via RSUs
Manuel Hidalgo Medina, a director at Guardant Health (NASDAQ: GH), gained 232 common shares through the exercise of restricted stock units (RSUs) on May 17, 2026. This transaction was a vesting event of equity compensation, not an open-market purchase, and occurred at a stated price of $0.00 per share. Following this, Medina now holds 1,889 common shares and 6,033 restricted stock units directly, with the initial RSU grant from July 2024 vesting over a four-year period.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 18, 2026
Guardant Health, Inc. announced that its Compensation Committee approved the granting of 143,898 restricted stock units (RSUs) to 267 new non-executive employees. These grants, made on April 21, 2026, with a grant date of May 11, 2026, are inducements for employment under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest annually over three years, contingent on continued employment.
Guardant Health (NASDAQ: GH) affiliate files Rule 144 notice for planned share resales
Guardant Health, Inc. (GH) has filed a Rule 144 notice indicating planned resales of restricted shares by an affiliate. The filing details planned sales of 80 shares with a December 15, 2025 lapse date and 36 shares with a February 15, 2026 lapse date. Additionally, it records past sales by Musa Tariq of 348 shares on March 18, 2026, and 116 shares on April 16, 2026, emphasizing the transparency requirements of Rule 144 for investor awareness.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. announced the granting of restricted stock units (RSUs) representing 143,898 shares of common stock to 267 new non-executive employees. These grants, approved on April 21, 2026, with a grant date of May 11, 2026, aim to incentivize employees to join the company as per Nasdaq Listing Rule 5635(c)(4). The RSUs will vest annually over three years, contingent on continued employment.
Guardant Health (GH) Q1 Revenue Jumps 48% to $301.7M on Strong Screening Growth
Guardant Health (GH) reported a 48% increase in Q1 2026 revenue, reaching $301.7 million, largely driven by a 600% surge in Screening revenue. Despite GAAP and non-GAAP net losses due to operational expansion, the company ended the quarter with $1.2 billion in cash and raised its full-year 2026 revenue guidance to $1.30-$1.32 billion. Operational milestones included expanding Guardant360 Tissue capabilities and securing FDA approval for Guardant360 CDx.
Guardant Health (GH) Q1 Revenue Jumps 48% to $301.7M on Strong Screening Growth
Guardant Health (GH) reported a 48% year-over-year revenue increase to $301.7 million in Q1 2026, driven by an over 600% surge in screening revenue. Despite operating expenses rising due to commercial expansion, the company achieved solid GAAP and non-GAAP gross margins and ended the quarter with $1.2 billion in cash. Guardant Health also raised its full-year 2026 revenue guidance to between $1.30 and $1.32 billion, representing 32% to 34% growth.
Have Guardant Health Insiders Been Selling Stock?
Guardant Health (NASDAQ:GH) has seen significant insider selling recently, with Co-CEO AmirAli Talasaz selling shares worth $5.0m and co-founder Helmy Eltoukhy selling $18m worth below the current price. While insiders own a healthy 3.8% of the company, the consistent selling without corresponding purchases raises caution for potential investors. The article highlights that such selling is a weak signal but suggests that insiders might view current valuations as high.
World Investment Advisors Purchases New Position in Guardant Health, Inc. $GH
World Investment Advisors has initiated a new position in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, acquiring 16,290 shares valued at approximately $1.66 million. Despite recent revenue growth of 39.4% year-over-year, Guardant Health's shares were down 3.8% to $94.92, largely due to an earnings miss against analyst expectations. Analysts maintain a "Moderate Buy" rating with a consensus price target of $129.42, even as company insiders have recently sold shares.
Why Guardant Health (GH) Stock Is Down Today
Guardant Health (GH) stock fell by 4.1% following the sale of 50,000 shares worth over $5 million by Co-CEO AmirAli Talasaz, raising investor concerns about short-term valuation or future performance. The company's shares are notably volatile, and this insider selling is seen as a significant event, though not fundamentally altering the perception of the business. Guardant Health has also seen previous drops, such as one related to an upsized convertible senior notes and public stock offering, which led to dilution concerns for existing shareholders.
Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors
Guardant Health announced that real-world data from its Guardant360 liquid biopsy played a crucial role in supporting the approval of ENHERTU in Japan for HER2-positive solid tumors. This approval, based on a comprehensive genomic profiling test, marks a significant step in personalized cancer treatment. The data demonstrated the effectiveness of Guardant360 in identifying eligible patients and supporting regulatory decisions.
Guardant Health Insider Sold Shares Worth $5,016,000, According to a Recent SEC Filing
An insider at Guardant Health sold shares valued at $5,016,000, as disclosed in a recent SEC filing. The details of the transaction, including the individual involved and the number of shares sold, indicate a significant insider sale at the company. This activity is noteworthy for investors tracking insider sentiment and company performance.
Guardant Health (GH) co-CEO family trust sells 50,000 shares
Guardant Health's Co-CEO and director, AmirAli Talasaz, reported an open-market sale of 50,000 shares of common stock on May 12, 2026, through the Talasaz and Eskandari 2017 Family Trust. The shares were sold at a weighted average price of $100.32, totaling approximately $5.02 million, with prices ranging from $100.30 to $100.34. Following this transaction, the family trust indirectly holds 2,096,504 shares of Guardant Health.
Guardant Health co-CEO Talasaz sells $5.02 million in stock
Guardant Health co-CEO AmirAli Talasaz sold 50,000 shares of common stock for approximately $5.02 million on May 12, 2026. The shares were sold at a weighted average price of $100.32 and are held indirectly by a family trust. This transaction follows a 142% surge in Guardant Health's stock price over the past year, and Talasaz still indirectly holds over 2 million shares.
[144] Guardant Health, Inc. SEC Filing
Guardant Health, Inc. has filed a Rule 144 notice with the SEC, detailing various classes of common stock and equity awards subject to potential sale. The filing includes 100,000 founder shares from 2018, along with stock options and restricted stock units issued between 2020 and 2024. This routine disposition notice provides key figures for these securities and clarifies the types of shares and their acquisition dates.
Guardant Health CMO resigns
This article reports that Guardant Health's Chief Medical Officer has resigned. No further details are provided regarding the CMO's identity or the reasons behind the resignation.
Guardant Health raises 2026 revenue outlook to $1.30B-$1.32B as Shield targets 230,000-245,000 tests
Guardant Health has increased its 2026 revenue outlook to $1.30 billion to $1.32 billion, up from the previous $1.20 billion to $1.22 billion. This revised forecast is driven by an updated volume target for its Shield blood tests, now expected to reach 230,000 to 245,000 tests, a significant increase from the prior estimate of 180,000 to 190,000 tests. The company provided these updates at its Analyst Day event, signaling strong anticipated growth.
Evercore ISI Keeps an “In Line” Rating on Guardant Health, Inc. (GH)
Evercore ISI maintained an "In Line" rating on Guardant Health, Inc. (GH) and increased its price target to $95 from $90 following the company's strong Q1 2026 financial report. Guardant Health reported a 48% year-over-year revenue growth to $301.7 million, driven by oncology sales, and subsequently raised its 2026 revenue outlook. The article also touches on the company's precision oncology focus and then transitions into a separate, unsolicited pitch for an AI stock investment.
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 36% Upside Potential in Precision Oncology
Guardant Health, Inc. (NASDAQ: GH) is positioned as a leader in precision oncology, attracting investor attention with its innovative diagnostic solutions and robust R&D investments. Despite financial challenges indicated by a negative forward P/E, strong revenue growth and overwhelming analyst confidence suggest a significant 36.42% upside potential from its current stock price. The company's advanced product suite and strategic collaborations highlight its commitment to expanding its influence in cancer diagnostics and treatment, making it a compelling investment in the healthcare sector.
Guardant Health (GH) Earnings Spotlight Revenue Growth Versus Persistent Losses Challenges Premium Valuation Narratives
Guardant Health (GH) recently reported its FY2025 results, showing Q4 revenue of US$281.3 million and a trailing twelve-month (TTM) revenue of US$982.0 million, reflecting strong revenue growth. However, the company continues to experience significant losses, with a TTM net income loss of US$416.3 million and quarterly EPS losses between US$0.74 and US$1.00. Despite a premium 12.5x P/S ratio and bullish analyst targets, persistent unprofitability and negative equity present challenges to its valuation, highlighting the need for revenue growth to translate into more efficient margins to support its rich multiple.
Guardant Health, Inc. (NASDAQ:GH) Q1 2026 Earnings Call Transcript
Guardant Health, Inc. reported strong financial results for Q1 2026, with total revenue increasing 48% year-over-year to $302 million, exceeding expectations despite an EPS miss. The growth was broad-based across its Oncology, Biopharma & Data, and Screening business lines, with significant momentum from its Shield colorectal cancer screening test and the Guardant360 Liquid and Tissue platforms. The company raised its full-year 2026 revenue guidance to $1.30 billion to $1.32 billion, driven by continued adoption of its oncology products and the successful commercial launch of Shield, including collaborations and marketing campaigns.
Guardant Health (GH) Earnings Spotlight Revenue Growth Versus Persistent Losses Challenges Premium Valuation Narratives
Guardant Health (GH) recently reported FY 2025 results, showing revenue growth to US$281.3 million in Q4, but persistent TTM net income losses of US$416.3 million. Despite a premium 12.5x P/S multiple and a DCF fair value significantly above its current share price, the company remains unprofitable and is not forecasted to reach profitability within three years. This situation creates a split view among investors, with some focusing on strong revenue growth potential while others are concerned about ongoing losses, negative equity, and cash burn.
Guardant Health : Q1 2026 Earnings Call
Guardant Health announced strong Q1 2026 results with a 48% increase in revenue, reaching $302 million, driven by significant growth in oncology and screening. Oncology revenue grew by 36% year-over-year, and screening revenue saw a substantial increase, supported by direct-to-consumer campaigns and partnerships. The company also highlighted advancements in its Smart Platform and InfinityAI, expanding its product portfolio and strategic biopharma collaborations.
Guardant Health CMO resigns
This article reports on the resignation of Guardant Health's Chief Marketing Officer (CMO). Further details are not available in the provided content.
Guardant Health: Q1 Earnings Snapshot
Guardant Health Inc. (GH) reported a first-quarter loss of $112.1 million, or 85 cents per share, which adjusted to 45 cents per share, exceeding Wall Street expectations. The oncology testing services provider also surpassed revenue forecasts, posting $301.7 million. The company projects full-year revenue between $1.3 billion and $1.32 billion.
Guardant Health (GH) Valuation Check After FDA Approval For Guardant360 CDx In ESR1 Mutated Breast Cancer
Guardant Health (GH) is under renewed scrutiny after its Guardant360 CDx liquid biopsy received FDA approval as a companion diagnostic for VEPPANU in ESR1 mutated breast cancer. The stock has seen significant price movement, with a 120% gain over the last year, prompting questions about whether it remains undervalued despite a current 28.1% undervaluation based on a $128.33 fair value estimate. However, a high P/S ratio of 12.5x, significantly above the industry average, raises concerns about valuation risk.
Guardant Health (GH) Valuation Check After FDA Approval For Guardant360 CDx In ESR1 Mutated Breast Cancer
Guardant Health (GH) has received FDA approval for its Guardant360 CDx liquid biopsy for ESR1 mutated advanced breast cancer, leading to renewed interest in the company. While the stock has seen a 120% gain over the past year, it is still considered undervalued by some metrics, with a fair value estimate of $128.33 against its current price of $92.26. However, concerns remain regarding heavy R&D spending, cash burn, and a high P/S ratio compared to the industry average.
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum
Guardant Health (NASDAQ:GH) reported a 48% year-over-year revenue increase in Q1 2026, driven significantly by its Shield colorectal cancer screening test, oncology, and biopharma segments. Despite strong revenue growth and raised full-year guidance, the company missed EPS expectations due to substantial investments in marketing for market share expansion. Guardant Health aims for cash flow breakeven by the end of 2027, relying on continued volume growth and operational efficiency.
Research Alert: Guardant Health: Testing Volume Growth Highlights Successful Q1 Results
Guardant Health (GH) reported strong Q1 results, exceeding consensus estimates for revenue and EPS, driven by significant growth in testing volumes and solid biopharma revenue. The company raised its full-year revenue guidance to $670-$680 million, reflecting confidence in its performance, particularly with the recent FDA approval of Shield. Analysts maintain a positive outlook, citing successful commercial execution and potential label expansion for screening indications.
Guardant Health: Q1 Earnings Snapshot
Guardant Health Inc. (GH) reported a Q1 loss of $112.1 million, or 85 cents per share, which adjusted to 45 cents per share, exceeding Wall Street's expectations. The company also surpassed revenue forecasts, posting $301.7 million, and anticipates full-year revenue between $1.3 billion and $1.32 billion.
Earnings Flash (GH) Guardant Health, Inc. Posts Q1 Adjusted Loss $0.45 per Share, vs. FactSet Est of $-0.45
Guardant Health, Inc. (GH) reported a Q1 adjusted loss of $0.45 per share, aligning with FactSet's estimate. The company announced this financial update on May 7, 2026, also providing full-year 2026 revenue guidance. This financial news follows other recent company updates, including FDA approval for one of its liquid biopsy tests.
Guardant Health earnings on deck as cancer test volumes surge
Guardant Health is set to report first-quarter earnings, with analysts anticipating increased losses despite strong revenue growth driven by surging cancer test volumes. Investors will be focused on the continued expansion of its Shield colorectal cancer screening and Guardant360 oncology tests, as well as the company's path to profitability. Recent FDA approval for its Guardant360 CDx test as a companion diagnostic for advanced breast cancer treatment is expected to further boost testing volumes.
Guardant Health: Q1 Earnings Snapshot
Guardant Health Inc. (GH) reported a Q1 loss of $112.1 million, or 85 cents per share, which was better than analysts' expectations of a 47-cent loss. The oncology testing company also exceeded revenue forecasts, posting $301.7 million against an expected $278.5 million. Guardant Health projects full-year revenue to be between $1.3 billion and $1.32 billion.
Guardant Health: Q1 Earnings Snapshot
Guardant Health Inc. reported a first-quarter loss of $112.1 million, or 85 cents per share, which adjusted to 45 cents per share and exceeded Wall Street's expectations. The oncology testing services provider also surpassed revenue forecasts, posting $301.7 million, and anticipates full-year revenue between $1.3 billion and $1.32 billion.
FDA Approval Adds New Catalyst To Guardant Health Valuation Story
Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic for VEPPANU, a treatment for advanced breast cancer. This approval, the third for Guardant360 CDx in ESR1 companion diagnostics, aims to broaden the test's clinical use and strengthen Guardant Health's ties with pharmaceutical companies. Despite recent short-term stock declines, the company has seen significant gains over the past year and three years, and analysts view it as undervalued.
Guardant Diagnostic Alliance Could Be A Game Changer For Nuvalent’s Targeted Oncology Strategy (NUVL)
Nuvalent (NUVL) has entered a multi-year collaboration with Guardant Health, utilizing Guardant Infinity's tissue and liquid biopsy tests for its oncology trials and commercialization. This alliance aims to enhance patient selection and streamline regulatory pathways for Nuvalent's kinase-targeted cancer therapies, potentially strengthening its companion diagnostic strategies. The collaboration could be a significant step in Nuvalent's investment narrative, supporting its pipeline and addressing regulatory milestones, although risks related to FDA decisions and future financing remain.
Guardant Health and Zydus to launch ‘Shield’ multi-cancer test in India
Guardant Health and Zydus Lifesciences have partnered to launch Guardant's Shield blood-based multi-cancer detection test in India, building on a 2023 collaboration. This initiative aims to provide an innovative, minimally invasive screening option in a market where 60-70% of cancers are detected too late. The Shield test detects DNA shed by tumors from a simple blood draw, covering cancers like gastric, esophageal, liver, colorectal, ovarian, lung, pancreatic, bladder, breast, and prostate cancer.
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Guardant Health announced its second-quarter 2024 financial results, exceeding expectations and leading the company to increase its revenue guidance for the full year 2024. This positive report highlights the company's strong performance in the healthcare sector, particularly in oncology and diagnostic solutions. The news also follows recent FDA approval for one of its key products and strategic collaborations.
Guardant Health India Launch: ₹1.4 Lakh Cancer Test par Hote Bawal? Zydus ne ki partnership!
Guardant Health, in partnership with Zydus Lifesciences, plans to launch its 'Shield' multi-cancer blood test in India. While this test offers a crucial solution for early cancer detection in a country with high mortality rates due to late diagnosis, its projected price of ₹1.4 Lakh, similar to the US cost, poses a significant affordability challenge for the Indian market. The regulatory environment and the need to align pricing with local conditions will be critical factors for its success.
